MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
1.795
+0.115
+6.85%
Opening 14:10 06/29 EDT
OPEN
1.700
PREV CLOSE
1.680
HIGH
1.825
LOW
1.670
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
3.535
52 WEEK LOW
1.201
MARKET CAP
178.03M
P/E (TTM)
-1.2652
1D
5D
1M
3M
1Y
5Y
1D
Caribou Biosciences CEO joins H.C. Wainwright cell therapy conference fireside chat
PUBT · 8h ago
Weekly Report: what happened at CRBU last week (0622-0626)?
Weekly Report · 10h ago
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Barchart · 13h ago
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Seeking Alpha · 3d ago
Weekly Report: what happened at CRBU last week (0615-0619)?
Weekly Report · 06/22 10:02
Caribou Biosciences Shareholders Decide Key Governance Matters
TipRanks · 06/18 21:19
Caribou Biosciences shareholders reject officer exculpation charter amendment at annual meeting
PUBT · 06/18 20:03
Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11
TipRanks · 06/16 10:16
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.